We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Tumor Cells in Blood Samples Predict Prostate Cancer Spread

By LabMedica International staff writers
Posted on 25 Nov 2016
Print article
Image: The Parsortix system uses a patented micro-fluidic technology in the form of a disposable cassette to capture and then harvest circulating tumor cells (CTCs) from blood (Photo courtesy of ANGLE).
Image: The Parsortix system uses a patented micro-fluidic technology in the form of a disposable cassette to capture and then harvest circulating tumor cells (CTCs) from blood (Photo courtesy of ANGLE).
A group of circulating tumor cells (CTC) in prostate cancer patient blood samples has been found which are linked to the spread of the disease and this is the first time these cell types have been shown to be a promising marker for prostate cancer spread.

There are around 46,500 new cases of prostate cancer each year in the UK, and around 11,000 people die from the disease each year. Epithelial to mesenchymal transition (EMT) is a critical step for tumor metastasis and in prostate cancer; circulating cells expressing the mesenchymal marker Vimentin (VIM) are cancer cells.

Scientists at the Barts Cancer Institute (London, UK) studied 81 samples from men with prostate cancer, comprising 38 untreated and 43 progressive diseases, and looked for cells that were gaining the ability to migrate and invade through the body. They optimized the Parsortix size and deformability-based platform (ANGLE, Plc, Guilford, UK) for the isolation of CTCs with both epithelial and mesenchymal properties and developed a multiple fluorescence in situ hybridization (FISH) rehybridization method to analyze multiple genomic changes on the CTCs after immunofluorescence signals were completely stripped.

The team analyzed several genomic regions, and detected genomic alterations in a similar proportion of CK+ and VIM+ groups of CD45- circulating cells. These genomic aberration results indicate that majority of VIM+/CD45- cells are circulating prostate cancer cells with EMT. Among the CTC types, the number of EMTing CTCs correlated the best with the presence of metastases and high risk localized disease and had a closest area under the ROC curve (AUC) to prostate specific antigen (PSA) level for distinguishing patients with detectable metastases.

The authors of the study concluded that they had developed a novel CTC detection and genomic analysis approach, which can efficiently analyze CTCs undergoing/undergone EMT. This greatly enhances our ability to investigate cancer metastasis process and to predict/monitor cancer progression using CTCs. Yong-Jie Lu, MD, PhD, the lead author said, “Our study shows that the number of these specific cells in a patient's sample is a good indicator of prostate cancer spreading. By identifying these cells, which have gained the ability to move through the body, we have found a potential new way to monitor the disease.” The study was presented at the National Cancer Research Institute Cancer Conference held in Liverpool, UK.

Related Links:
Barts Cancer Institute
ANGLE
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.